Glucosamine

Glucosamine: A Comprehensive Reference

1. Identity: Chemical Names, Natural Sources, and Common Forms

Chemical Identity

Glucosamine (C₆H₁₃NO₅) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids. It is also known by the synonym chitosamine. Glucosamine is chemically formed by replacing one hydroxy group of a glucose molecule with an amino group. D-glucosamine occurs naturally in the cartilage in the form of glucosamine-6-phosphate, which is synthesized from fructose-6-phosphate and glutamine.

Glucosamine is part of the structure of two polysaccharides, chitosan and chitin, and is one of the most abundant monosaccharides. Glucosamine is an amino sugar and a prominent molecule in the biochemical pathways of synthesis of glycosylated proteins and lipids.

Natural Sources

Glucosamine is an endogenous aminomonosaccharide synthesized from glucose, and is a precursor for the synthesis of glycosaminoglycans and glycoproteins. Glucosamine naturally found in all human tissues is particularly found at high concentrations in connective tissues, and at highest concentration in articular cartilage. Glucosamine is made in the body from glucose using adenosine triphosphate (ATP) and the amine from glutamine.

Glucosamine is a natural sugar that exists in the fluid around the joints, as well as in animal bones, bone marrow, shellfish, and fungi. It is produced commercially by the hydrolysis of shellfish exoskeletons or, less commonly, by fermentation of a grain such as corn or wheat.

Besides being a chitin monomer, glucosamine is a precursor for synthesizing glycosaminoglycans (GAGs), namely, hyaluronic acid, heparan sulfate, and keratan sulfate. All these components are found in the synovial fluid in the joint cavities, cartilage, and other connective tissues.

Commercial Forms and Preparations

There are several forms of glucosamine, including glucosamine sulfate, glucosamine hydrochloride and N-acetyl glucosamine. These supplements are not considered interchangeable. N-acetyl glucosamine (GlcNAc), glucosamine hydrochloride, and glucosamine sulfate are three major derivatives of glucosamine-based nutraceuticals available in oral formulation.

Most glucosamine supplements are made from chitosans obtained from crustacean sources prepared using sulfate. Glucosamine may be obtained by acid hydrolysis of the shells of lobsters, crabs, shrimps, or prawns. An alternative, non-crustacean source also exists: glucosamine can be derived from fermented fungal biomass containing chitin, with suitable starting materials including fungal sources derived from Aspergillus sp., Penicillium sp., and Mucor sp. As a product of fungal biomass, this form of glucosamine does not pose a hazard to persons who have shellfish allergies.

Although many products in the marketplace are labelled as "glucosamine sulfate," they are often not true compounds but rather unreacted mixtures of glucosamine hydrochloride and a salt such as potassium or sodium sulfate. Such mixed salts are used rather than glucosamine sulfate alone since the latter is unstable due to its highly hygroscopic nature and the facility with which its amino group oxidizes if not completely saltified.

In most of Europe, glucosamine is approved as a medical drug and is sold in the form of glucosamine sulfate. In the United States, glucosamine is not approved by the Food and Drug Administration (FDA) for medical use in humans. Because glucosamine is classified as a dietary supplement in the United States, the FDA requires evidence of its safety, but not its effectiveness, as long as it is not marketed as a treatment for any medical condition.

Glucosamine is a popular nutritional supplement and natural component of cartilage that is frequently combined with chondroitin sulfate and used for osteoarthritis and nonspecific joint pain. Some supplements combine glucosamine with other ingredients, such as chondroitin sulfate, shark cartilage, or methylsulfonylmethane, known as MSM.

2. Historical Discovery and Early Use

Glucosamine was discovered in 1876 from chitin by Georg Ledderhose, who named it glycosamine. Later in 1902, it was synthesized and purified by Hermann Leuchs, a student of Emil Fischer. The stereochemistry was not fully determined until the 1939 work of Walter Haworth.

Glucosamine was mainly introduced on the world-wide market as a food supplement but with the aim to improve symptoms in patients with osteoarthritis or joint pain or function. The use of crystalline glucosamine sulfate as a pharmaceutical-grade preparation was pioneered by the Italian firm Rottapharm, whose proprietary product DONA became widely referenced in European clinical research. The use of glucosamine supplements became popular in the 1990s after several best-selling books touted it as a hedge against osteoarthritis.

Unlike many herbal supplements that derive from centuries-old traditional healing systems, glucosamine as an isolated supplement has no substantiated history of use in pre-modern traditional medicine. Its clinical application is largely a 20th-century development arising from biochemical research into cartilage composition rather than from ethnobotanical or ethnopharmacological traditions.

3. Key Constituents and Active Compounds

Endogenous Role

Glucosamine is a naturally occurring building block for complex long-chain glycosaminoglycans that are linked to a core protein in proteoglycan molecules (aggrecans), and form part of the cartilage matrix. It is used in the biosynthesis of proteoglycans and glycosaminoglycans (GAGs) as a proposed substrate for the synthesis of these important cartilage components and perhaps a direct stimulator of their synthesis. Glucosamine can be thought of as a building block that helps restore the proteoglycan-rich matrix and thus balance cartilage catabolism and anabolism.

Pharmacological Forms: Distinctions Between Salt Forms

The two primary supplement forms — glucosamine sulfate (GS) and glucosamine hydrochloride (GHCl) — deliver identical glucosamine ions but differ in their co-ions and potentially in bioavailability, stability, and clinical performance. Most positive long-term European clinical trials have used a specific crystalline form of pharmaceutical-grade glucosamine sulfate, while the large NIH-funded GAIT trial in the United States used glucosamine hydrochloride. Glucosamine hydrochloride was used instead of the glucosamine sulfate formulation in the GAIT trial, a distinction that has been cited as a source of difference in results between major studies.

After oral administration of glucosamine sulfate, 90% is absorbed and helps to build articular cartilage.

4. Mechanisms of Action

Anabolic and Structural Effects

In vitro and in vivo studies have uncovered glucosamine's mechanisms of action on articular tissues (cartilage, synovial membrane and subchondral bone) and justified its efficacy by demonstrating structure-modifying and anti-inflammatory effects at high concentrations.

The anabolic effects of glucosamine were primarily thought to be attributable to its capacity for providing building blocks for the synthesis of GAGs by chondrocytes. Glucosamine is naturally present in the cartilage (which acts like a cushion) in your joints. It is part of a substance called glycosaminoglycan, which acts as a building block for your cartilage.

Anti-Catabolic Effects

Glucosamine exerts anti-catabolic potency, seen by its inhibition of the expression and/or activity of catabolic enzymes such as phospholipase A2, matrix metalloproteinases, or aggrecanases. Another study confirmed the potency of glucosamine to inhibit the expression and activity of aggrecanase-2 (ADAMTS-5) in transiently transfected cell lines. Glucosamine is able to inhibit the MMP synthesis, and further proteoglycan degeneration is therefore prevented. Glucosamine also inhibits aggrecanase by suppression of glycosylphosphatidylinositol-linked proteins.

Anti-Inflammatory Effects

Glucosamine is demonstrated in vitro to reduce prostaglandin E2 (PGE2) production and inhibit activation of the nuclear factor kappa B (NF-κB) pathway, thus inhibiting the cytokine intracellular signaling cascade in chondrocytes and synovial cells. In OA, glucosamine induces reversal of the pro-inflammatory and joint-degenerating effects of interleukin-1 (IL-1).

It is believed that glucosamine sulfate prevents glycosaminoglycan and collagen degradation by down-regulating the production of inflammatory cytokines via decreased prostaglandin E2 synthesis, inhibition of nuclear factor kappa B (NF-κB), and decreased expression of catabolic enzymes such as metalloproteinases.

Current evidence has revealed that glucosamine exhibits anti-inflammatory effects by reducing the levels of pro-inflammatory factors (such as tumour necrosis factor-alpha, interleukin-1, and interleukin-6) and enhancing the synthesis of proteoglycans that retard cartilage degradation and improve joint function. Additionally, glucosamine improves cellular redox status, reduces OA-mediated oxidative damages, scavenges free radicals, upregulates antioxidant proteins and enzyme levels, inhibits the production of reactive oxygen species, and induces autophagy to delay OA pathogenesis.

Effect on Synovial Membrane

In the same study, glucosamine hydrochloride also reduced osteophyte formation and was shown to inhibit the production of the pro-inflammatory cytokine IL-6 and to upregulate the production of the anti-inflammatory cytokine IL-10 by the synovial membrane.

Caveats on In Vitro vs. In Vivo Extrapolation

Several authors have proposed that the therapeutic doses used in clinical practice did not allow the identification of proteoglycan synthesis as a mechanism of action of glucosamine. Therefore, extrapolation of the in vitro data to the in vivo situation should be done with great caution.

5. Scientific Evidence by Area of Use

5.1 Osteoarthritis of the Knee — Pain and Function

Studies of glucosamine and chondroitin for pain in knee osteoarthritis (OA) have had conflicting results. Some, including a major National Institutes of Health (NIH)-sponsored study, found little or no evidence that glucosamine and chondroitin can relieve pain, but several other studies indicated that it can.

The GAIT Trial (2006): The largest and most methodologically rigorous randomized controlled trial of glucosamine for knee OA was the NIH-funded Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT). The multicenter, double-blind, placebo- and celecoxib-controlled GAIT evaluated the efficacy and safety of glucosamine and chondroitin as a treatment for knee pain from osteoarthritis. The study included 1,583 patients, 22% (354) of whom had moderate to severe pain. Patients were randomized to glucosamine (1,500 mg/day), chondroitin (1,200 mg/day), both glucosamine and chondroitin, celecoxib (200 mg/day), or placebo for 24 weeks. Participants taking the positive control, celecoxib, experienced statistically significant pain relief versus placebo — about 70% of those taking celecoxib had a 20% or greater reduction in pain versus about 60% for placebo. Overall, there were no significant differences between the other treatments tested and placebo.

The glucosamine formulation used was glucosamine hydrochloride rather than glucosamine sulfate, which is more commonly available as a supplement in the US. This has been noted as a potential limitation in interpreting results in comparison with European trials that used crystalline glucosamine sulfate.

A 2007 review of the available research concluded that there was "compelling evidence" that glucosamine sulfate (but not hydrochloride) slowed the progression of knee and hip osteoarthritis. This finding was confirmed by a 2013 meta-analysis of 19 glucosamine trials which concluded that while neither form of glucosamine appeared significantly more effective than placebo at symptom improvement, glucosamine sulfate alone showed efficacy in improving physical function in knee OA as measured by the Lequesne Index in trials lasting more than 24 months.

In 252 outpatients with OA of the knee, those treated with 1,500 mg/day glucosamine sulfate for 4 weeks had a significantly higher decrease in the Lequesne's index than those receiving a placebo, with response rates within the same range as those observed with the intramuscular formulation (55 vs. 38% in evaluable patients; 52 vs. 37% in an intention-to-treat analysis).

5.2 Osteoarthritis of the Knee — Joint Space Narrowing (Structure Modification)

A few studies have looked at whether glucosamine or chondroitin or the combination can have beneficial effects on joint structure in people with OA. Some but not all of these studies found evidence that chondroitin or a glucosamine-chondroitin combination might help, but the improvements seen in most studies may be too small to make a difference to patients.

The structural sub-study of GAIT followed participants for 24 months at nine US sites. This study was undertaken to evaluate the effect of glucosamine and chondroitin sulfate, alone or in combination, as well as celecoxib and placebo, on progressive loss of joint space width in patients with knee OA. Patients continued to receive glucosamine 500 mg three times daily, chondroitin sulfate 400 mg three times daily, the combination, celecoxib 200 mg daily, or placebo over 24 months. The mean joint space width loss at 2 years in knees with OA in the placebo group, adjusted for design and clinical factors, was 0.166 mm. None of the active treatment groups produced a statistically significant reduction compared to placebo in this extension study.

5.3 Osteoarthritis of the Hip

In 2017, the American Academy of Orthopaedic Surgeons published a clinical practice guideline on management of osteoarthritis of the hip that concluded that moderate strength evidence does not support the use of glucosamine sulfate for hip osteoarthritis. This conclusion was based on the one high-quality study that was identified. That study, published in 2008, included 222 participants, who received 2 years of treatment with glucosamine sulfate or a placebo. Glucosamine was no better than placebo in terms of effects on pain, joint function, or joint structure.

5.4 Clinical Practice Guidelines

The clinical practice guidelines strongly recommend against the use of glucosamine in people with hip, knee, and/or hand OA. Although a common dietary supplement, there is little clinical evidence that it is effective for relief of arthritis or pain, and it is not an approved prescription drug in most countries, although it is listed as a medicinal product in Europe. Worldwide, there are no clinical organizations that recommend use of glucosamine as a treatment for arthritis.

In 2004, the FDA declared there was insufficient evidence for supplement manufacturers to state that glucosamine was effective for treating arthritis, joint degeneration, or cartilage deterioration, a position remaining in effect as of 2025.

5.5 Rheumatoid Arthritis

Early research suggests that oral use of glucosamine hydrochloride might reduce pain related to rheumatoid arthritis. However, the evidence base for rheumatoid arthritis is substantially smaller and less conclusive than for osteoarthritis, and no clinical practice guidelines support its use in this indication.

5.6 Cardiovascular Disease and Mortality — Observational Evidence

A series of large prospective observational studies, primarily using UK Biobank data, has identified associations between habitual glucosamine use and reduced cardiovascular and all-cause mortality. These findings are hypothesis-generating but do not establish causality.

A prospective cohort study used UK Biobank data, enrolling 466,039 participants without CVD at baseline who completed a questionnaire on supplement use. These participants were enrolled from 2006 to 2010 and were followed up to 2016. After adjustment for age, sex, body mass index, race, lifestyle factors, dietary intakes, drug use, and other supplement use, glucosamine use was associated with a significantly lower risk of total CVD events (hazard ratio 0.85, 95% confidence interval 0.80 to 0.90), CVD death (0.78, 0.70 to 0.87), coronary heart disease (0.82, 0.76 to 0.88), and stroke (0.91, 0.83 to 1.00).

In a large prospective cohort study of 495,077 participants from the UK Biobank who were followed for a median of 8.9 years, regular use of glucosamine supplement was associated with a lower all-cause mortality (HR=0.85; 95% CI, 0.82 to 0.89), after adjusting for multiple variables.

One study used the National Health and Nutrition Examination Survey (NHANES), which included a sample of approximately 16,700 participants; 658 (4%) of them who consumed glucosamine/chondroitin for at least a year had a 27% lower overall mortality and a 58% lower cardiovascular mortality.

These are observational associations and are subject to residual confounding — users of glucosamine supplements may have systematically healthier lifestyles or greater health-seeking behaviours than non-users, which cannot be fully adjusted for in analyses. No randomised controlled trials have tested glucosamine specifically for cardiovascular outcomes.

5.7 Gout

A UK Biobank cohort of 436,594 participants without prior gout at baseline was enrolled to assess the relationship between glucosamine supplementation and incident gout. At baseline, 53,433 (22.1%) females and 30,685 (15.8%) males reported habitual glucosamine use. During a median follow-up period of 12.1 years, 1,718 (0.7%) females and 5,685 (2.9%) males developed gout. After multivariable adjustment, glucosamine use was associated with a significantly lower risk of incident gout in females (hazard ratio 0.81, 95% CI 0.71–0.92), but not in males (HR 1.05, 95% CI 0.97–1.13). This sex-differential finding warrants further investigation and the study is observational in design.

5.8 Other Areas Under Investigation

Large UK Biobank observational studies have reported associations between habitual glucosamine use and reduced risks of various outcomes beyond joints and cardiovascular disease. These include associations with lower sepsis incidence and post-sepsis mortality, lower risk of dementia and Alzheimer's disease, and reduced cancer mortality. However, mediation analysis in one sepsis study revealed that only 1.2–7.0% of the association for sepsis and 2.8–5.4% of the association for 28-day mortality following sepsis were mediated through inflammatory biomarkers, including C-reactive protein and systemic immune-inflammation index. The observed associations might be partially mediated through inflammatory pathways. All of these associations are derived from observational data and are not established through interventional trials.

6. Body Systems and Health Areas

• Musculoskeletal System: Glucosamine is a natural component of cartilage and is widely used as an over-the-counter nutritional supplement purported to decrease the pain and cartilage loss of osteoarthritis.
• Connective Tissue: Glucosamine is found at high concentrations in connective tissues, and at highest concentration in articular cartilage.
• Joint Fluid: Glucosamine is an endogenous substance, a normal constituent of the polysaccharide chains of cartilage matrix and synovial fluid glucosaminoglycans.
• Cardiovascular System: Observational data suggest associations with reduced CVD risk, though the mechanism is not established in interventional trials.
• Immune/Inflammatory Pathways: Glucosamine has recently garnered interest for its potential anti-inflammatory effects.

7. Dosage Forms and Dosages Reported in Studies

Glucosamine sulphate is typically dosed at 1,500 mg daily in clinical use. This dose has been administered in both divided (three doses of 500 mg) and single daily regimens. In the GAIT trial, patients were randomized to glucosamine (1,500 mg/day), chondroitin (1,200 mg/day), both glucosamine and chondroitin, celecoxib (200 mg/day), or placebo for 24 weeks.

In the GAIT structural sub-study, patients received glucosamine 500 mg three times daily, chondroitin sulfate 400 mg three times daily, or the combination, over 24 months.

In a study of 252 outpatients with OA of the knee, those treated with 1,500 mg/day glucosamine sulfate for 4 weeks had a significantly higher decrease in the Lequesne's index than those receiving a placebo.

Standard daily use of 1,500 mg has been studied for up to 36 months without major safety concerns.

Glucosamine is available primarily in oral form (capsules, tablets, and powders). Intravenous and intramuscular formulations have been used in early research but are not common in current practice. After oral administration of glucosamine sulfate, 90% is absorbed.

8. Safety Considerations and Drug Interactions

General Tolerability

Overall, the evidence suggests that glucosamine and chondroitin are generally effective and well-tolerated, particularly for managing osteoarthritis and joint pain. Consistent dosing strategies and favorable safety profiles across a diverse range of studies support their continued use in clinical practice, but further research is needed related to other disease states.

Mild stomach upset, nausea, or heartburn are occasionally reported as side effects.

Warfarin Interaction

Using the United States FDA MedWatch database, 20 reports of glucosamine or glucosamine-chondroitin sulfate use with warfarin associated with altered coagulation (manifested by increased INR, or increased bleeding or bruising) were identified. In some cases, a decrease in the supplement dosage was followed by a return of the INR to the previous therapeutic range. Similarly, a decrease in warfarin dosage was followed by a decrease in INR in one patient who received long-term warfarin therapy. One report described an intraventricular bleed and subdural hematoma, which resulted in a persistent vegetative state.

The World Health Organization (WHO) adverse drug reactions database documented 21 spontaneous reports of increased INR associated with glucosamine use, 17 of which resolved when glucosamine was stopped.

Use of glucosamine may inhibit platelet aggregation. There are also reports describing enhanced anticoagulant effects when glucosamine has been taken with warfarin, and it has been suggested that glucosamine should be used with caution in patients taking antiplatelet agents.

Chemotherapy Interactions

Theoretically, glucosamine may induce resistance to some chemotherapy agents and may interact with doxorubicin and etoposide; because of the potential clinical significance of this interaction, glucosamine should not be used concomitantly with these agents.

Blood Glucose and Diabetes

Reports that oral glucosamine supplementation at usual doses adversely affects glucose metabolism in subjects with impaired glucose tolerance have raised concerns that glucosamine should be contraindicated in individuals with diabetes and those at risk for developing it. However, a systematic review of the evidence found a more reassuring picture: in long-term clinical trials, including those containing subjects with type 2 diabetes or 'pre-diabetes', glucosamine produced a non-significant lowering of fasting blood glucose concentrations in all groups of subjects treated for periods of up to 3 years. Based on available evidence, glucosamine appears to have no effect on fasting blood glucose levels, glucose metabolism, or insulin sensitivity at any oral dose level in healthy subjects, individuals with diabetes, or those with impaired glucose tolerance.

Clinical trials have not demonstrated clinically significant effects on fasting glucose, HbA1c, or insulin sensitivity in diabetic patients. Nevertheless, owing to limitations in study design, conclusions based on studies that report adverse effects of glucosamine on insulin sensitivity and glucose tolerance in pre-diabetic subjects are suspect, and no definitive long-term studies of glucosamine use for individuals with pre-diabetes are available.

Shellfish Allergy

Glucosamine may interact with warfarin (increasing INR) and is contraindicated in shellfish allergy unless synthetic forms are used. The glucosamine molecule itself does not contain shellfish allergens, but cross-contamination during processing of shellfish-derived products remains a practical concern.

Hepatotoxicity

Glucosamine has been implicated in isolated case reports in causing clinically apparent liver injury, but the role of glucosamine as opposed to other herbal components or contaminants has not been shown, and liver injury due to glucosamine or chondroitin must be very rare if it occurs at all. Reports of hepatic injury from glucosamine are few — less than a dozen in the published literature — and always limited by the lack of proof of purity of the dietary supplement used.

Regulatory Status Summary

In the United States, glucosamine is not approved by the FDA for medical use in humans. Because glucosamine is classified as a dietary supplement, the FDA requires evidence of its safety, but not its effectiveness, as long as it is not marketed as a treatment for any medical condition. In most of Europe, glucosamine is approved as a medical drug and is sold in the form of glucosamine sulfate.

References

• PubChem — D-Glucosamine (CID 439213), NIH National Library of Medicine
• PMC — A Flood of Health Functional Foods: What Is to Be… (PMC4452808)
• LiverTox — Glucosamine, NCBI Bookshelf, NIH
• Wikipedia — Glucosamine
• NCCIH — Glucosamine and Chondroitin for Osteoarthritis: What You Need To Know
• NCCIH — Arthritis and Complementary Health Approaches: What the Science Says
• NCCIH — Osteoarthritis: In Depth
• NCCIH — Arthritis and Complementary Health Approaches (Clinical Digest)
• PMC — The Safety and Efficacy of Glucosamine and/or Chondroitin in Humans: A Systematic Review (PMC12250884)
• PMC — Role of Glucosamine in the Treatment for Osteoarthritis (PMC3456914)
• Arthritis Research & Therapy — Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis?
• Scientia Pharmaceutica — Multifaceted Protective Role of Glucosamine against Osteoarthritis: Review of Its Molecular Mechanisms
• StatPearls — Glucosamine Sulfate, NCBI Bookshelf, NIH
• PMC — A Review of Articular Cartilage Pathology and the Use of Glucosamine Sulfate (PMC155438)
• PMC — Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA (PMC3150191)
• Current Medical Research and Opinion — A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated
• New England Journal of Medicine — Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis (GAIT, Clegg et al. 2006)
• PubMed — The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from GAIT (Sawitzke et al. 2008)
• PubMed — The NIH Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), J Pain Palliat Care Pharmacother 2008
• PMC — Associations of habitual glucosamine supplementation with incident gout: a large population based cohort study (PMC9524004)
• PMC — Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank (PMC6515311)
• PMC — Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study (PMC7286049)
• Mayo Clinic Proceedings — Association of Glucosamine Supplementation and Incidence of Heart Failure
• PMC — A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals (PMC3042150)
• PubMed — Potential glucosamine-warfarin interaction resulting in increased INR: case report and review of the MedWatch database (Knudsen et al. 2008)
• Memorial Sloan Kettering Cancer Center — Glucosamine: Integrative Medicine
• PMC — Recent advancement of glucosamine and N-acetyl glucosamine production using microorganisms: A review (PMC12168751)
• European Medicines Agency — Glucomed referral